Major Study Links Early Treatment to Reduced Risk of Dilated Cardiomyopathy, Large Trial Underway
Madrid, Spain – A groundbreaking study analyzing data from over 3,000 patients has revealed a potential link between early treatment with renin-angiotensin system (RAS) inhibitors and a decreased likelihood of developing dilated cardiomyopathy (DCM), a leading cause of heart failure. The findings are fueling a major clinical trial across Spain and Holland,investigating whether preventative treatment can delay or even prevent the onset of this serious heart condition.
The research, spearheaded by Dr. pablo García Pavía, Head of the Heart Insufficiency and Family Heart Section at Puerta de Hierro University Hospital, identified several factors associated with DCM advancement. While age and sex were expected contributors, the study uncovered a meaningful association: patients already on RAS inhibitors before diagnosis showed a lower risk of progressing to the disease.”This observation strongly supports the hypothesis that early pharmacological intervention could be beneficial,” explains Dr. David Fatkin,adding that key questions remain: “Should therapies be administered proactively to at-risk individuals? And if so,at what point would intervention be most effective?”
To address these questions,Dr. García Pavía is leading a multi-center clinical trial involving 37 hospitals. the trial focuses on individuals carrying genetic alterations known to cause DCM, comparing the effects of RAS inhibitor treatment against a placebo. Participants will be monitored for three years to determine if the treatment demonstrably reduces the risk of disease development. The study is being conducted in collaboration with the Spanish Cardiovascular Research Center (CIBERCV).
DCM affects approximately one in 250 people globally, impacting an estimated 32 million individuals worldwide. The condition weakens and enlarges the left ventricle, hindering the heart’s ability to pump blood efficiently. As the disease progresses, it can lead to heart failure, arrhythmias, blood clots (potentially causing stroke or heart attack), valve leakage, and even sudden cardiac death.
Further analysis revealed that specific clinical factors also contribute to DCM risk.The research showed that pre-existing high blood pressure and type 2 diabetes increased susceptibility,while a history of atrial fibrillation doubled the chances of developing the disease.
Importantly, the most common genetic cause of DCM, truncating mutations in the TTN gene, can be identified through a simple blood test. However, until now, the extent to which these mutations increased risk, and the influence of other factors, remained unclear. The results of the ongoing clinical trial are anticipated to provide crucial insights into preventative strategies for this debilitating condition.
